This CPB has been revised with the following: (i) for psoriatic arthritis continuation of therapy section, added "functional status and CRP" to the list of signs and symptoms, and (ii) added chest x-ray as an example for TB screening for latent disease, and removed chest x-ray as an example for active disease screening. The TB testing requirement has been moved to the 'Other' section. This CPB has been revised to state that concomitant use of risankizumab-rzaa (Skyrizi) with any other biologic drug or targeted synthetic drug is considered experimental, investigational, or unproven 'for the same indication'. Previous version did not specify indication.